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Abstract
Background: Thymoquinone (TQ) is a compound extracted from Black Caraway seeds of Nigella Sativa and is
active against various cancers. Cisplatin (CDDP) is the most active chemotherapeutic agent in Lung Cancer. Here
we report activity of TQ against non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines
alone and in combination with Cisplatin (CDDP).
Methods: For proliferation MTT assay, cell viability trypan blue assay and for apoptosis Annexin-V FITC assay were
used in NCI-H460 and NCI-H146 cell lines. Inhibition of invasion by TQ was assessed using Matrigel assay and its
affect on release of various cytokines was determined using RayBio Human Cytokine detection kit. Mouse xenograft
model using NCI-H460 was used to determine in vivo activity of TQ and CDDP. Inhibition of LPS induced NF-B
expression by TQ was determined using transgenic mice expressing a luciferase reporter.
Results: TQ was able to inhibit cell proliferation, reduce cell viability and induce apoptosis. TQ at 100 μM and
CDDP at 5 μM inhibited cell proliferation by nearly 90% and the combination showed synergism. TQ was able to
induced apoptosis in both NCI-H460 and NCI-H146 cell lines. TQ also appears to affect the extracellular
environment inhibiting invasion and reducing the production of two cytokines ENA-78 and Gro-alpha which are
involved in neo-angiogenesis. Using a mouse xenograft model we were able to demonstrate that combination of
TQ and CDDP was well tolerated and significantly reduced tumor volume and tumor weight without additional
toxicity to the mice. In the combination arms (TQ5 mg/kg/Cis 2.5 mg/kg) tumor volume was reduced by 59% and
(TQ20 mg/kg/Cis 2.5 mg/kg) by 79% as compared to control which is consistent with in vitro data. TQ down
regulated NF-B expression which may explain its various cellular activities and this activity may prove useful in
overcoming CDDP resistance from over expression of NF-B.
Conclusions: Thus TQ and CDDP appear to be an active therapeutic combination in lung cancer.
Background
Lung cancer is the leading cause of cancer related death
in United States. In the US alone it is estimated that in
the year 2008, approximately 215,020 new cases of lung
cancer were diagnosed and an estimated 161,480 deaths
were reported. The mortality from lung cancer is more
than the combined mortality from breast, prostate and
colorectal cancers [1].
The two major histological types of lung cancer are
non-small cell lung cancer (NSCLC) accounting for
about 85% of cases and small cell lung cancer (SCLC)
accounting for 15% of cases [2]. Approximately 16% of
NSCLC patients are diagnosed with early stage or
localized disease and are treated with surgical resection
[3]. Systemic chemotherapy is indicated in adjuvant
treatment [4] as well as in advanced stages of NSCLC
and is also used in treatment of all stages of SCLC. The
most active chemotherapeutic agent for the treatment of
NSCLC and SCLC is cisplatin (CDDP) which is used in
a doublet with other agents such as paclitaxel, gemcita-
bine and docetaxel [5]. The response rate in NSCLC
from CDDP alone is about 20% and in combination
with a second agent improves to about 26% [6].
Recently, new agents have been approved for treat-
ment of lung cancer including erlotinib [7] and bevaci-
zumab [8]. However the overall 5 year survival from
lung cancer has not changed appreciably in the past 25
years and remains dismal at 16% [1]. * Correspondence: sjafri@lsuhsc.edu
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Sativa, Ranunculaceae family), is an annual herb that
grows in countries bordering Mediterranean Sea, Paki-
stan and India.
The seed has been used as a natural remedy for more
than 2000 years to promote health and treat diseases.
Medicinal properties of black seeds have even been
mentioned by the Prophet of Islam, Muhammad (Peace
be upon him) and its use was recommended for various
ailments [9].
Thymoquinone (TQ) is the bioactive constituent of
the volatile oil of black seed. It has been shown to exert
anti-inflammatory, anti-oxidant and anti-neoplastic
effects both in vitro and in vivo [10]. TQ has been
shown to exhibit anti-tumor activities on cells lines
derived from ovarian, breast and colon cancers [11].
TQ has also been shown to potentiate the anti-tumor
activity of CDDP in Ehrlic ascites sarcoma (EAC) and
simultaneously protected against CDDP nephrotoxicity
[12]. Using both mouse and other rodent models it was
shown that TQ when administered orally after mixing
in drinking water ameliorated the nephrotoxicity from
CDDP and also improved CDDP therapeutic index.
Combining the most active chemotherapeutic drugs
with agents that target specific pathways offers a power-
ful approach to cancer treatment and may counteract
the many ways that human cancer cells can become
drug resistant. The platinum atom of CDDP forms cova-
lent bonds to the N7 positions of purine bases to afford
primarily 1, 2- or 1, 3-intra strand cross links and a
lower number of inter strand cross links which even-
tually leads to apoptosis [13]. There is evidence that
CDDP induces increased expression of NF-Ba n dt h a t
this activity results in increased CDDP resistance [14].
NF-B controls cellular proliferation in part by increas-
ing expression of cyclin D1 which moves cells from G1
to S phase [15]. TQ has been reported to suppress tumor
necrosis factor (TNF) induced NF-B expression in
human chronic myeloid leukemia cells (KBM-5) which
may also explain why cells undergo apoptosis [16]. TQ
was shown to suppress expression of NF-B activation
pathway through modulation of p65 subunit of NF-B
and inhibition of IBa kinase (IKK) [16].
T h u si nt h ep r e s e n ts t u d yw eh a v ec o m b i n e dan o n -
cell cycle specific active chemotherapy drug CDDP
which causes direct DNA damage with another agent
TQ which targets the cell cycle at the transition from
G1 to S phase hypothesizing the combination of TQ
and CDPP will enhance the efficacy of CDDP and possi-
bly overcome its resistance by suppression of CDDP
induced over expression of NF-B. TQ by suppressing
NF-B, should also affect tumor angiogenesis and
metastasis [15].
Materials and methods
In Vitro experiments
Cell culture
NSCLC cell line NCI-H460 was generously provided by
Dr James A. Cardelli (Louisiana State University Health
Sciences Center, Shreveport, LA). SCLC cell line NCI-
H146 was purchased from American Type Culture Col-
lection (ATCC). Cells were grown in RPMI 1640 (Cell
gro) supplemented with 10% Fetal bovine serum (FBS),
1% Penicillin and Streptomycin in a humidified incuba-
tor with 5% CO2 at 37°C.
1) Cell proliferation assay
NCI-H460 cells (NSCLC cell line) were seeded at a den-
sity of 5,000 cells per well in 96 well plates and after 24
hrs cells were treated with 80 μM and 100 μMT h y m o -
quinone (TQ) (Sigma Aldrich, St Louis MO) in 0.1%
DMSO, 1.25 μM, 2.5 μM and 5.0 μM Cisplatin (CDDP)
(Sigma Aldrich, St Louis MO) or TQ and CDDP at var-
ious combinations as noted. These doses of TQ and
CDDP were chosen based on IC50 calculated from ear-
lier experiments (Results not shown). There were four
wells per condition and experiment was repeated twice
to validate results. MTT (3-(4,5 Dimethylthiazol -2-yl)-
2,5-dipheynyltetrazolium bromide) assay was used to
determine live cells at 24, 48 and 72 hrs after treatment
as per the manufacturer’s (Invitrogen) instructions.
2) Cell viability assay
Cell viability of the SCLC cell line NCI-H146 was
assessed using the trypan blue cell viability assay. About
5,000 cells/well were seeded in 6 well plates using
appropriate media and left in incubator overnight. At 24
hrs cells were treated with TQ at doses 20, 40, 60, 80
and 100 μM with appropriate DMSO concentration as
the control. Cells were collected 2 hours later by low
speed centrifugation and trypan blue viability assay was
performed with the aid of a Coulter counter.
3) Apoptosis assay
Apoptosis in the NCI-H460 and NCI-H146 cell lines
was detected using Annexin-V FITC Apoptosis detec-
tion kit I (BD Pharmingen). 24 hrs after treatment with
100 μM TQ both cell lines were removed from the
plates using trypsin in the case of NCI-H460 only. Cells
were extensively washed with PBS and adjusted to 1 ×
10
6 cells/ml and stained with Annexin V FITC and pro-
pidium iodine as per the manufacture’s instruction. Pre-
sence of apoptosis was detected using a Cytomics FC
500 Beckman Coulter Flowcytometry (Coulter, Inc,
Hialeah Fl).
4) Cytokine Assay
The effect of TQ on release of cytokines was assessed
using the RayBio Human Cytokine Antibody Array C
S e r i e s2 0 0 0 .( R a y B i oT e c h .I n c .N o r c r o s s ,G A ) .C e l l s
grown in serum free media in 12 well plates at a density
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μM and the media collected after 24 hours. The col-
lected media was applied on cytokine membranes which
were then exposed to a photographic film for approxi-
mately 30 minutes after which the films were developed
in a dark room. The resulting images were analyzed
using Image J Software to measure expression of various
cytokines.
5) Invasion assay
The effect of TQ on tumor cell invasion was assayed
using a Matrigel based assay. Trans well inserts (Corn-
ing Life Science, Corning, NY) with 8 micron diameter
pores were coated with 20 μL of Matrigel (BD Bios-
ciences), dried, and subsequently rehydrated first using
750 μL of serum free medium, followed by the addition
of complete medium. NCI-H460 cells at a density of
25,000 cells in 100 μL per insert were applied. After 2
hrs cells were treated with DMSO or TQ at 20, 40 or
80 μM. After 24 hrs the non-invasive cells were
removed and the cells that had invaded into the Matri-
gel were detected by fixation with 10% neutral buffered
formalin followed by staining with hematoxylin. Mem-
branes were removed from inserts, mounted on slides
and invading cells counted using a microscope with a
40× objective.
6) In Vivo Experiments
a) Animals 5-6 weeks old female Severe combined
immunodeficiency mice (SCID) mice were obtained
from Harlan Laboratory (Harlan Laboratories, Inc,
Indianapolis, IN) and maintained under pathogen free
conditions in a temperature and humidity controlled
animal care facility with a 12 hours light dark cycle. The
animal protocol for this experiment has been approved
by the Committee of Animal Care and Use, LSUHSC in
accordance with National Institutes of Health (NIH)
guidelines. All procedures were conducted under sterile
conditions. Mice were allowed access to sterile food and
water ad libitum.
b) Maximum Tolerated Dose Groups of 3 or 4 female
SCID mice were randomized to receive TQ alone or in
combination with CDDP. TQ was prepared by dissol-
ving in cremophor: ethanol: PBS (1:1:4) and CDDP was
prepared by dissolving in PBS. TQ was given at 5, 10
and 20 mg/kg subcutaneously (s.c.) on Monday, Wed-
nesday and Friday for 3 weeks either alone or in combi-
nation with CDDP at 5 mg/kg i.p once a week for 3
weeks. MTD was considered the highest dose in which
no mortality was observed. At the end of three weeks
mice were sacrificed and liver and kidneys were har-
vested for histological analysis.
c) Mouse xenograft experiment For the xenograft
study, female SCID mice (age 5-6 weeks old) were
shaved on the flank two days prior to injection with
tumor cells. Xenografts were obtained by injecting NCI-
H460 2 × 10
6 cells subcutaneously into the right flank
of each mouse. Tumors were allowed to grow for one
week and when tumor volume reached approximately
20 mm
3 mice were randomized to 6 groups with 10
mice in each group. Tumor volume was calculated using
the formula V = (L × W
2)×0 . 5w h e r eV =v o l u m e ,L=
length, W = width.
Mice were randomized into following 6 treatment
groups with 10 mice in each group and treated for 3
weeks.
1) Control
2) TQ alone 5 mg/kg (s.c) M, W, F
3) TQ alone 20 mg/kg (s.c) M, W, F
4) CDDP alone 2.5 mg/kg (i.p) every Monday
5) CDDP 2.5 mg/kg+TQ5 mg/kg (combination)
6) CDDP 2.5 mg/kg+TQ20 mg/kg (combination)
Tumor volume and body weight was measured M, W,
F for three weeks during the course of study. At the end
o ft h r e ew e e k s( D a y2 6 )m i c ew e r es a c r i f i c e db yC O 2
asphyxiation in a pre charged chamber and tissue sam-
ples were obtained for histological analysis. Mean tumor
weight was also calculated after harvesting tumors.
7) NF-B expression in lung cancer xenografts
NF-B in the xenografts was assayed by Western blot
analysis on snap-frozen xenograft tumor specimens
which were pooled in duplicate for a total of 5 samples
per group. Briefly, aliquots of the xenograft samples
were lysed in Radio-Immunoprecipitation Assay_RIPA
(Buffer) containing protease and phosphatase inhibitor
cocktails and EDTA (Thermo Scientific, Rockford, IL).
Proteins (40 μg) were resolved by SDS-PAGE [17] and
the proteins were transferred electrophoretically to
PVDF membranes (0.45 μm, Millipore Corp., Billerica,
MA) [18]. Western blot assays were conducted using
antibodies against phospho-Ser529 NF-B (1:200) and
unphosphorylated NF-B (1:500), followed by the appro-
priate secondary antibodies and enhanced chemilumi-
nescent detection [19]. The intensities of
immunostained proteins were determined using Image J
software http://rsb.info.nih.gov/ij/ mean intensities cal-
culated as a ratio of phospho-NF-Bt ot o t a lN F - B,
and normalized to Hela cell lysates run on the same gel.
8) NF-B suppression by TQ
We assessed suppression of NF-Bb yT Qu s i n gt h e
light producing animal model (LPTA) NF-B- R E - l u c
(Oslo) which is a transgenic mice expressing a luciferase
reporter whose transcription is dependent on NF-B
[20]. The luminescence from luciferase can be detected
real time using an ultrasensitive camera IVIS 100 Ima-
ging system (Caliper Life sciences, Hopkinton MA).
Lipopolysaccharide (LPS) or Tumor necrosis factor-
alpha (TNF-a) are used to induce NF-B activity.
Jafri et al. Journal of Experimental & Clinical Cancer Research 2010, 29:87
http://www.jeccr.com/content/29/1/87
Page 3 of 11Initially 5-8 mice/group were injected with either vehicle
alone or TQ 5 mg/kg or 20 mg/kg subcutaneously and
images obtained to detect any effect of TQ on NF-B
expression with 2.5 mg D-luciferin substrate adminis-
tered 15 minutes prior to each imaging without prior
induction with LPS. Two days later mice were injected
with vehicle or 5 mg/kg or 20 mg/kg TQ subcuta-
neously, followed 30 minutes later by injection of LPS
(2.7 mg/kg i.p) with mice then imaged at 3 hrs and 24
hrs interval to assess NF-B activity with 2.5 mg D-luci-
ferin substrate administered 15 minutes prior to each
imaging. The luminescence intensity was quantitated in
regions of interest (ROI) using Living Image® 3.0 soft-
ware (Caliper Life Sciences, Inc. Hopkinton, MA).
Statistical analysis
For the MTT assay factorial analyses of variance
(ANOVA) were used to determine the effect of TQ,
CDDP and control with the time. Student-Newman-
Keuls test was used to determine statistical significance
with P value < 0.05 considered significant.
For the mouse xenograft studies and for NF-B
expression using the luciferase reporter mouse SAS®
Proc Mixed was used and least squares means (LS-
means) were estimated. The Bonferroni method was
used for multiple comparisons adjustments on the dif-
ferences of LS-means.
Results
1) TQ inhibits proliferation alone and in combination with
CDDP
In the MTT assay TQ at 80 and 100 μM showed signifi-
cant inhibition of cell proliferation most noticeable at 24
hrs. The effect of TQ alone on cell proliferation waned
with time with less activity observed at 48 and 72 hrs
suggesting more frequent dosing of TQ may be required
to demonstrate a sustained effect. CDDP alone at 24 hrs
was not every active as compared to TQ but at 48 and
72 hrs showed significant inhibition of cell proliferation.
The combined effect of TQ and CDDP on cell prolif-
eration was most noticeable at 48 and 72 hrs with 89%
inhibition of cell proliferation observed at 72 hrs
(Figure 1, Figure 2, Figure 3).
2) TQ enhances the effect of Cisplatin with synergism
between the two agents
When the NCI-H460 cells were grown in the presence
o ra b s e n c eo fT Qa n dC D D Pi tw a sa p p a r e n tt h a tt h e
combined effect of TQ and CDDP was more than the
each agent alone. To confirm the presence of synergism
we determined the Combination index (CI) for two
combination treatment groups using Calcuysyn software
with CI < 1 indicating synergism, CI > 1 indicating
antagonism and CI = 1 indicating an additive effect.
Synergism was most noticeable at 72 hrs in the groups
TQ 80 and CDDP 1.25 (CI = 0.789) (Figure 4) as well
as TQ 100 and CDDP 2.5 (CI = 0.761).
The combination of TQ (100 μM) and CDDP (5 μM)
at 72 hrs showed 89% inhibition of cell proliferation
(Figure 3).
3) TQ inhibits cell viability in a SCLC cell line
Measurements of cell viability in a SCLC cell line NCI-
H146 were determined using trypan blue assay. 24 hrs
after exposure to TQ 20-100 uM on average only 50%
of cells were viable as shown in (Figure 5).
4) Apoptosis assay
To determine if the decrease in proliferation and viabi-
lity were a result of TQ induced apoptosis in the two
cell lines, cells were assayed by Annexin V staining after
exposure to TQ. After 24 hours treatment with 100 μM
TQ about 87.59% of NCI-H460 cells and 88.1% of NCI-
H146 cells were positive for Annexin-V compared to
2.0% and 34.5% Annexin V positive cells in the DMSO
treated cell (Figure 6).
3) TQ suppresses expression of cytokines involved in
neo-angiogenesis
To assess the effect of TQ on release of various cyto-
kines we assayed the culture media to determine if TQ
affected expression of cytokines in NCI-H460 cell line.
Of the panel of various cytokines measured using
Figure 1 The figure shows results of MTT assay for cell
proliferation using NSCLC cell line NCI-H460 at 24, 48 and 72
hrs with control group representing 100% cell proliferation
depicted by extreme left solid line. TQ alone is more active at 24
hrs and CDDP more active at 48 and 72 hrs. The combination of TQ
and CDDP is more active than each agent alone with up to 89%
inhibition of cell proliferation at 72 hrs with combination of TQ 100
μM and CDDP 5 μM. (*) shows significant inhibition by TQ at each
level of CDDP (p < 0.05).
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two cytokines ENA-78 and Gro-alpha were significantly
lower in the media of cells exposed to 100 μMT Qa s
compared to control. The mean integrated density as
measured by Image J Software for ENA-78 in the con-
trol treated group was 7083 as compared to 1732 in the
TQ treated group and for Gro-alpha in the control
group mean integrated density was 9970 as compared to
1877 in the TQ treated group (See figure 7-8).
4) TQ inhibits invasion in a Matrigel assay
Because of the known effects of TQ on decreasing speci-
fic cytokines production and the known effects of cyto-
kines on tumor cell invasion, we determined the effects
of TQ on tumor cell invasion as assayed by growth into
Matrigel. TQ at three concentrations (20, 40 and 80
μM) significantly inhibited invasion as compared to con-
trol (P < 0.05). Inhibition of invasion was greatest at 40
μM where inhibition was 85% as compared to control
(Figure 9).
5) Maximum tolerated dose (MTD) and toxicity study
Prior to determining the effect of TQ on the growth of
xenografts we studied the toxicity of TQ and CDDP
alone and in combination as noted in the Methods to
determine the maximum tolerated dose (MTD). Besides
vehicle control (group 1), TQ was administered (s.c) on
Monday, Wednesday, and Friday for 3 weeks at doses of
5 mg/kg (group2), 10 mg/kg (group3) and 20 mg/kg
(group4). CDDP was administered (i.p) once a week for
3 weeks at 5 mg/kg (group 5) alone or in combination
with TQ at 5 mg/kg (group 6), 10 mg/kg (group 7) and
20 mg/kg (group 8). No mortality was observed in
groups 1-6 though mice in group 6 lost 20-40% of body
weight. 50% of the mice in group 7 and 75% in group 8
died. Histological analysis was performed on kidneys,
Figure 2 The figure shows results of MTT assay for cell
proliferation using NSCLC cell line NCI-H460 at 24, 48 and 72
hrs with control group representing 100% cell proliferation
depicted by extreme left solid line. TQ alone is more active at 24
hrs and CDDP more active at 48 and 72 hrs. The combination of TQ
and CDDP is more active than each agent alone with up to 89%
inhibition of cell proliferation at 72 hrs with combination of TQ 100
μM and CDDP 5 μM. (*) shows significant inhibition by TQ at each
level of CDDP (p < 0.05).
Figure 3 The figure shows results of MTT assay for cell
proliferation using NSCLC cell line NCI-H460 at 24, 48 and 72
hrs with control group representing 100% cell proliferation
depicted by extreme left solid line. TQ alone is more active at 24
hrs and CDDP more active at 48 and 72 hrs. The combination of TQ
and CDDP is more active than each agent alone with up to 89%
inhibition of cell proliferation at 72 hrs with combination of TQ 100
μM and CDDP 5 μM. (*) shows significant inhibition by TQ at each
level of CDDP (p < 0.05).
Figure 4 Combination Index (CI) between TQ and CDDP at 72
hrs using NCI-H460. CI 0.789 at TQ 80 μMolar and CDDP 1.25
μMolar. CI 0.939 at TQ 100 μMolar and CDDP 1.25 μMolar. The
Combination Index (CI) was calculated using Calcusyn software with
CI of <1 suggesting synergism between TQ and CDDP using cell
line NCI-H460.
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Page 5 of 11Figure 5 Results of trypan blue cell viability assay using SCLC cell line NCI-H460 2 hrs after treatment with increasing concentration
of TQ. Cell viability decreased with increasing concentration of TQ and on average only 50% of cells were viable 2 hrs after treatment with
various concentration of TQ.
Figure 6 Flowcytometry data showing apoptosis in both NSCLC (NCI-H460) and SCLC (NCI-H146) cell lines 24 hrs after treatment with
TQ 100 μM. 87.59% of NCI-H460 cells and 88.1% of NCI-H146 cells were positive for Annexin-V 24 hrs after treatment with TQ. Upper
row represent NCI-H460 cells and Lower row NCI-H146. Left column represents control treated and the right column represents TQ treated.
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pathological abnormalities noted in the lungs and heart
of any of the mice. In the analysis of the kidneys no
pathological abnormality was observed in groups 1-4
(TQ treated alone) except for the presence of 5% focal
proximal tubular damage noted in group 4 (TQ 20 mg/
kg). In group 5 (CDDP5 mg/kg alone) there was proxi-
mal tubular damage noted in 20-30% of the samples. In
the combination groups [7,8] diffuse tubular damage
and acute tubular necrosis (ATN) was noted in 40-80%
of samples. Mice in these groups also lost significant
body weight and appeared dehydrated. This enhance-
ment of nephrotoxicity may be related to poor by
mouth intake and dehydration resulting in ATN. On the
basis of these studies MTD was determined to be as
follows: CDDP 2.5 mg/kg i.p. weekly along with TQ at
5 mg/kg and 20 mg/kg subcutaneously Monday, Wed-
nesday and Friday for the xenograft study.
6) Mouse xenograft study
In the mouse xenograft study as described in methods
section after 4 weeks of tumor growth no mortality
occurred. However, the combination of TQ and CDDP
had striking effects on tumor volume (Figure 10). TQ
alone at 5 mg/kg was not active. The higher dose of TQ
Figure 7 Effect of TQ on release of various cytokines was
determined using RayBio Human Cytokines Antibody Array C
Series 2000. TQ treated cell media was applied to cytokine
membranes which were then exposed to a photographic film for 30
minutes and developed in a dark room. The three membranes
represent various cytokines whose presence can be detected using
this technique. Dots represent presence or absence of various
cytokines which were then quantitated using image J Software
expressed as mean integrated density.
Figure 8 TQ suppressed expression of cytokines ENA-78 and
GRO-alpha significantly as compared to control. These cytokines
are implicated in neo-angiogenesis.
Figure 9 Effect of TQ on invasion was assessed calculating
number of cells invading into Matrigel. TQ at increasing
concentration inhibited cell invasion as compared to control.
Figure 10 Results of Mouse xenograft study. Tumor volume with
time: Change in tumor volume is shown in various treatment arms
over the study period. Mice were treated with either s.c. TQ every
Monday, Wednesday and Friday or CDDP i.p. once a week or
combination.Mice in combination treatment arms (TQ20 mg/kg +
CDDP 2.5 mg/kg) had the smallest tumor volume at the end of 3
week study period.
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tumor volume although the effect was marginally signifi-
cant (p 0.075). Cisplatin alone at 2.5 mg/kg reduced
tumor volume significantly (p < 0.001). The effect on
tumor volume was greatest in the combination arms
with significant reduction of tumor volume by 59% with
the combination of (5 mg/kg TQ and 2.5 mg/kg CDDP)
(p = 0.036) and by 79% with combination of (20 mg/kg
TQ and 2.5 mg/kg of CDDP) (p = 0.0016).
The decrease in tumor volume was mimicked by a
similar decrease in tumor weight in all treatment arms
except TQ alone at 5 mg/kg (Figure 11).
7) TQ suppresses NF-B expression in vivo
TQ by itself had no effect on basal luciferase activity
and NF-B expression. (Figure 12 top panels). However,
at 3 hrs after treatment with LPS the increased lumines-
cence indicating activation of NF-B was suppressed by
prior treatment with TQ at 5 and 20 mg/kg as com-
pared to control though this effect was not statistically
significant (P < 0.10). This effect however was not
o b s e r v e da t2 4h r sp o i n ti n t e r v a l ,w h e r em o s to fl u m i -
nescence had returned to baseline (Figure 12, Table 1).
8) Effect of TQ on expression of NF-B in the xenografts
The xenografts were further evaluated for the effects of
TQ on NF-B expression with tumor lysates from xeno-
grafts analyzed by western blot for levels of phosphory-
lated NF-Ba sar a t i oo ft o t a lN F - B. Significant
reduction in ratio of phosphor-Ser529 NF-B/NF-B
were seen in xenografts from mice treated with combi-
nation of TQ (20 mg/kg) and CDDP (2.5 mg/kg) but
not with TQ or CDDP alone (P < 0.05) (Figure 13).
Discussion
We evaluated anti-neoplastic effect of TQ alone and
more importantly in combination with CDDP in a
NSCLC and a SCLC lung cancer cell line using both in
vitro and in vivo techniques. TQ appeared to be active
both in a NSCLC and a SCLC cell line. TQ inhibited pro-
liferation of NSCLC cell line NCI-H460 and induced
apoptosis. Similarly cell viability of SCLC cell lines NCI-
H146 was decreased and cells underwent apoptosis after
exposure to TQ. More importantly TQ acted synergisti-
cally with CDDP in a NSCLC cell line which is very
encouraging. This inhibitory effect of TQ on lung cancer
cell proliferation is not unique as recently TQ has been
shown to inhibit growth of prostate, pancreatic and colon
c a n c e r s[ 1 1 ]H o w e v e r ,t h i si st h ef i r s tt i m et h a tw eh a v e
demonstrated anti-neoplastic effects of TQ in Lung Can-
cer using both a NSCLC and a SCLC cell line. Combina-
tion of TQ and CDDP is also unique and the results are
encouraging as the two drugs have differing mechanism
of action, the former being a cell cycle specific and the
latter non-cell cycle specific. The dose of TQ used in
these experiments may not be feasible in humans.
Recently, Banerjee et al [21] have shown that more
potent synthetic analogues of TQ can be prepared which
can potentially be developed for future human use.
Besides anti-proliferative and pro-apoptotic effects TQ
appears to affect tumor microenvironment. TQ reduced
Figure 11 M e a nt u m o rw e i g h ta td a y2 6f o re a c hg r o u p .( * )
means significant inhibition by addition of TQ (p < 0.05).
Figure 12 LPS induced NF-B expression using luciferase
reporter mice. Upper row: NF-B expression pre-screen; Middle
row NF-B expression 3 hrs after LPS induction; Lower row NF-B
expression 24 hrs after LPS induction. Mice when pre-treated with
TQ 5 mg/kg (Right column) showed less NF-B expression at 3 hrs
as compared to control treat mice (Left column). Level of NF-B
expression returned to baseline 24 hrs after exposure to LPS. The
luminescence from luciferase was detected real time using an
ultrasensitive camera IVIS 100 Imaging system. The luminescence
intensity was quantitated in regions of interest (ROI) using Living
Image® 3.0 software as shown in table 1.
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which are involved in inflammation and angiogenesis
[22]. ENA-78 has been shown to be elevated in NSCLC
surgical samples and correlates with tumor growth and
vascularity [23]. ENA-78 and GRO belong to a family of
ELR+ve CXC cytokines and are potent promoters of
angiogenesis [24]. Similarly using Matrigel assay we
were able to demonstrate that TQ inhibited invasion of
NCI-H460 cells into Matrigel. Inhibition of tumor
angiogenesis by TQ and its effects on invasion have
recently been shown by others as well [25]. Thus TQ
appears to be an agent that not only affects cell prolif-
eration but may also influence the extra-cellular envir-
onment and immune system.
As far as toxicity from TQ is concerned there appears
to be no significant toxicity demonstrated from use of
TQ alone in our MTD study using female SCID mice.
When TQ was used alone no mortality was observed,
mice maintained their weight and no significant tissue
damage was observed on histological analysis of liver
a n dk i d n e y .I nt h eM T Ds t u d yw h e r eah i g h e rd o s eo f
CDDP (5 mg/kg) was used in combination with TQ
mortality was observed in mice and most of the tissue
damage was noticed to be in kidneys. It appears that the
nephroprotective effects of TQ against CDDP as demon-
strated in a previous study [12] were not reproduced in
our model. The Combination of TQ with higher doses
of CDDP also contributed to significant weight loss and
apparent dehydration which may have resulted in wor-
sening of kidney damage from CDDP and ultimately
their demise. However, TQ alone or in combination
with lower dose of CDDP (2.5 mg/kg i.p. weekly) did
not appear to have any direct toxic effect on kidneys or
liver. In the mouse xenograft model in combination
with CDDP at 2.5 mg/kg there was weight loss but no
mortality or tissue damage was observed on histological
analysis of kidneys and liver.
In the mouse xenograft model TQ alone at 20 mg/kg
was active. The combination of TQ and CDDP was
more active than each agent alone. The combination of
(20 mg/kg TQ and 2.5 mg/kg of CDDP) reduced tumor
volume by 79% without additional toxicity to the mice.
These results are very encouraging and consistent with
our in vitro data and show that TQ and CDDP is an
effective therapeutic combination in lung cancer.
TQ by itself was shown to suppress LPS-induced NF-
Ba c t i v a t i o ni nt h eN F - B -Luc-Re mice which is con-
sistent with known properties of TQ [16]. We substan-
tiated this finding in the luciferase mouse with the
analysis of p- NF-B expression in lysates of the xeno-
grafts (Figure 13). The effect on NF-B was present in
the combination of CDDP and TQ as presumably the
combination is blocking multiple pathways that activate
the NF-B. As altered NF-B expression is implicated in
CDDP resistance [14] the suppression of NF-Bb yT Q
may provide a mechanism for overcoming CDDP resis-
tance which makes TQ an exciting compound to
develop in combination with CDDP. Supporting our
results is recent publication by Banerjee et al [26] in
which TQ was shown to augment anti-tumor activity of
Gemcitabine and Oxaliplatin in pancreatic cancer by
down regulation of NF-B.
Recently it has been shown that the effects of TQ are
broad with the demonstration that TQ inhibits Polo like
kinases (PLKs) [27], family of serine/threonine protein
kinases which control critical steps in passage of cells
through the M phase of the cell cycle [28].Also PLK1 is
Figure 13 Ratio of p-NF-kB/NF-kB in tumors.T h ex e n o g r a f t s
were evaluated for the effects of TQ on NF-B expression with
tumor lysates from xenografts analyzed by western blot for levels of
phosphorylated NF-B as a ratio of total NF-B. V = Vehicle, TQ =
Thymoquinone, C = CDDP at 2.5 mg/kg. Significant reduction in
ratio of p NF-B/NF-B were seen in xenografts from mice treated
with combination of TQ (20 mg/kg) and CDDP (2.5 mg/kg).
Table 1 ROI values of Female Luciferase reporter mice*
Control TQ5 mg/kg TQ20 mg/kg
Pre-Screen 15,490 +/- 2,108 17,155 +/- 8,957 11,990 +/- 3,031
LPS 3 hrs 176,375 +/- 63,901 89,457 +/- 24,084 75,923 +/- 33,793
LPS 24 hrs 23,978 +/- 5,501 24,177 +/- 6,830 39,823 +/- 13,631
NF-B expression was measured by quantitating the luminescence intensity in regions of interest (ROI) using Living Image® 3.0 software (Caliper Life Sciences,
Inc. Hopkinton, MA). (*) ROI values include +/- standard error (n = 3-4) obtained using Living Image Software version 3.0. ROI values are equal in the mice pre-
treated with vehicle or TQ showing TQ has no effect on NF-B expression. 3 hrs after LPS injection ROI values representing NF-B expression are much lower in
mice pre-treated with TQ at 5 and 20 mg/kg though not statistically significant (P < 0.10) as compared to control suggesting pre-treatment with TQ suppresses
NF-B expression. ROI return to baseline at 24 hrs in both groups.
Jafri et al. Journal of Experimental & Clinical Cancer Research 2010, 29:87
http://www.jeccr.com/content/29/1/87
Page 9 of 11over expressed in NSCLC and has prognostic significance
[29]. Therefore in using TQ in NSCLC we may target cell
cycle not only at G1-S phase but also at M phase.
Conclusions
Thus in conclusion, in this paper we have demonstrated
anti-proliferative and pro-apoptotic activities of TQ in
both a NSCLC and a SCLC cell lines. It also appears
that there may be synergism between TQ and CDDP.
This combination was active in vivo as demonstrated by
the mouse xenograft sudy. By suppressing NF-B, TQ
may be able to overcome CDDP resistance and enhance
its efficacy. Thus TQ or likely synthetic analogues of
TQ should be developed for possible future human use
not only in lung cancer but in possibly other tumor
types as well.
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